Replies to post #37853 on Intellipharmaceutics International Inc. (IPCI)

[cjstocksup]

There is no way that IPCI will stay below dollars on this drug approval news IMO. Look at all the other big pharma's they also have low priced drugs that get approved and run insane. We have a tiny float the Nasdaq news just coincided and no one has seen any news on the FDA approval yet because it has not hit. A few investors here knew about it! IMO We run back to yearly highs pre split once the news is out. That would be over $10.00. Just look at the tiny float. No news on the FDA drug approval hit and every Nasdaq investors loves stocks with tiny floats of less than 5 to 6 million shares. They are easy to run from below a dollar to over $10.00, $20.00 etc. depending on how high they run them. I have been in many!

[WeeZuhl]

Stay tuned for the next pump: Nasal/oral HAL study results will be described in a PR as a great success, but no data will be revealed to prove it is true.

Sorry, I was wrong. The next attempted pump will be an IND for oxy IR with PODRAS. Hmmmmmm. Didn't they receive Fast Track for oxy ER with PODRAS back in 2015? Yaaaaaaaaawwwwwwwwnnnnnnnnnnnn.


https://www.intellipharmaceutics.com/news-media/press-releases/detail/187/intellipharmaceutics-submits-investigational-new-drug

("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths.

Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.

This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.